Market Overview - The Sci-Tech Innovation Board (STAR Market) index decreased by 0.48%, closing at 991.64 points, with a total trading volume of 2.486 billion shares and a turnover of 83.57 billion yuan, resulting in a weighted average turnover rate of 1.45% [1] - Among the tradable stocks on the STAR Market, 274 stocks closed higher, with 5 stocks rising over 10% and 11 stocks rising between 5% and 10%. Conversely, 304 stocks closed lower [1] Trading Activity - The distribution of turnover rates shows that 3 stocks had turnover rates exceeding 20%, 7 stocks had rates between 10% and 20%, 32 stocks had rates between 5% and 10%, 69 stocks had rates between 3% and 5%, 275 stocks had rates between 1% and 3%, and 201 stocks had rates below 1% [1] - The stock with the highest turnover rate was Qingyun Technology, which closed up 15.31% with a turnover rate of 38.58% and a transaction amount of 908 million yuan. Other notable stocks included Sailun Biology and Youke Technology, with turnover rates of 27.40% and 22.11%, respectively [1][3] Sector Performance - In terms of industry performance, the pharmaceutical and biotechnology sector had the most stocks with turnover rates exceeding 5%, totaling 11 stocks, followed by machinery and equipment with 6 stocks, and electronics with 5 stocks [2] - Among high turnover stocks, 20 stocks experienced net inflows of main funds, with Youke Technology, Shijia Optics, and Hecuan Technology seeing the largest net inflows of 161 million yuan, 46.85 million yuan, and 46.42 million yuan, respectively [2] Leverage Fund Movements - A total of 25 stocks received net purchases from leveraged funds, with notable increases in financing balances for Zhongyou Technology, Gai Lun Electronics, and Shijia Optics, which increased by 101 million yuan, 80.49 million yuan, and 78.69 million yuan, respectively [2]

Group 1 - The A-share innovative drug concept has experienced a volatile rebound, with Changshan Pharmaceutical rising over 16% to reach a historical high [1] - Lianhua Technology increased by more than 9%, indicating positive market sentiment towards innovative drug companies [1] - Other companies such as Anglikang, Sailun Bio, Wanbangde, and Zhongsheng Pharmaceutical also saw gains, reflecting a broader trend in the sector [1]

Core Viewpoint - The article highlights the critical issue of snakebite treatment in China, emphasizing the importance of timely administration of antivenom and the challenges faced in its production and availability [1][4][11]. Group 1: Snakebite Statistics and Impact - Globally, snakebites result in 81,000 to 138,000 deaths annually, with China experiencing 250,000 to 280,000 cases each year, primarily affecting individuals over 50 years old [7][11]. - The peak incidence of snakebites in China occurs from April to October, with July to September being the highest risk months [7]. Group 2: Antivenom Production Challenges - The production of antivenom faces significant challenges, including limited types available, complex production processes, and insufficient market incentives [9][11]. - Currently, the only producer of antivenom in China, Serun Biotech, can only manufacture four types of antivenom, which limits treatment options for various snake species [9][11]. Group 3: Treatment Protocols and Guidelines - The "golden two hours" is crucial for effective snakebite treatment, with the need for antivenom administration emphasized within this timeframe [4][5]. - The National Health Commission's guidelines specify that antivenom should be used when certain symptoms are present, such as significant swelling or systemic toxicity [5][10]. Group 4: Advances in Antivenom Research - Research from the U.S. has led to the development of broad-spectrum antivenom capable of neutralizing 19 types of snake venom, offering hope for improved treatment options [2][12]. - Serun Biotech is also advancing clinical trials for antivenom and rapid testing kits to shorten treatment times [12]. Group 5: Traditional and Alternative Treatments - Traditional Chinese medicine approaches snakebite treatment by categorizing snake venoms and employing methods to clear toxins, with specific herbal remedies being commonly used [6][11]. - The efficacy of antivenom and traditional remedies differs, with antivenom specifically neutralizing venom, while traditional methods focus on symptom relief [6][11].

Summary of Key Points Core Viewpoint - Sairun Bio (688163) has shown a positive stock performance with a closing price of 18.46 yuan as of May 30, 2025, reflecting a 3.36% increase from the previous week [1] Company Announcements - Sairun Bio announced a cash dividend of 0.2 yuan per share, with the record date set for June 4, 2025 [2] - The total cash dividend distribution amounts to 21,644,000 yuan, based on a total share capital of 108,220,000 shares [2] - The ex-dividend date and cash dividend payment date are scheduled for June 5, 2025 [2] Taxation Details - For individual shareholders holding unrestricted shares for over one year, the dividend income is exempt from personal income tax [2] - For those holding shares for less than one year, a 10% tax applies, resulting in a net dividend of 0.18 yuan per share [2] - Qualified Foreign Institutional Investors (QFII) and Hong Kong market investors will also receive a net dividend of 0.18 yuan per share after a 10% withholding tax [2]

Core Points - The company announced a cash dividend of 0.2 yuan per share, totaling 21,644,000 yuan based on a total share capital of 108,220,000 shares [1][2] - The profit distribution plan was approved at the annual shareholders' meeting on May 16, 2025, for the fiscal year 2024 [1] Distribution Plan - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [1] - The distribution will be executed through the clearing system of the China Securities Depository and Clearing Corporation, with specific procedures for shareholders who have completed designated trading [3][4] Taxation Details - For individual shareholders holding unrestricted shares for over one year, the dividend income is exempt from personal income tax, resulting in a net cash dividend of 0.2 yuan per share [5][6] - Shareholders holding shares for less than one year will have taxes calculated upon the transfer of shares, with the actual cash dividend remaining at 0.2 yuan per share until then [5] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, leading to a net cash dividend of 0.18 yuan per share [7] - Other institutional investors will be responsible for their own tax payments, receiving a gross cash dividend of 0.2 yuan per share [8]

Core Viewpoint - Shanghai Sailun Biotechnology Co., Ltd. announced its 2024 annual profit distribution plan, which includes a cash dividend of 0.2 RMB per share, totaling 21,644,000 RMB for all shareholders [1][2]. Distribution Plan - The profit distribution plan was approved at the company's annual shareholders' meeting on May 16, 2025 [1]. - The total share capital before the distribution is 108,220,000 shares, with a cash dividend of 0.2 RMB per share (before tax) [1][2]. Relevant Dates - The key dates for the distribution are as follows: - Record date for shareholders: Not specified - Ex-dividend date: Not specified - Cash dividend payment date: Not specified [1]. Implementation Method - Cash dividends for unrestricted circulating shares will be distributed through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch [1]. - Shareholders who have completed designated transactions can receive their cash dividends on the payment date at their designated securities firms [1]. Taxation Information - For individual shareholders holding unrestricted circulating shares: - If the holding period exceeds 1 year, the cash dividend is exempt from individual income tax, resulting in a net payment of 0.2 RMB per share [2][3]. - For holding periods within 1 year, the company will not withhold income tax at the time of distribution, but tax will be calculated based on the holding period when the shares are sold [2][3]. - The actual tax burden varies based on the holding period, with a maximum tax rate of 20% for shares held for 1 month or less [3][4]. - For qualified foreign institutional investors (QFII), a 10% withholding tax applies, resulting in a net payment of 0.18 RMB per share [5]. Contact Information - For inquiries regarding this equity distribution, shareholders can contact the company's board secretary office at 021-64959122 [6].

证券代码：688163 证券简称：赛伦生物 公告编号：2025-014 上海赛伦生物技术股份有限公司2024年年度权益 分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/4 | 2025/6/5 | 2025/6/5 | 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本108,220,000股为基数，每股派发现 金红利0.2元（含税），共计派发现金红利21,644,000.00元。 是否涉及差异化分红送转：否 每股分配比例 每股现金红利0.2元 相关日期 1. 发放年度：2024年年度 2. 分派对 ...

Core Viewpoint - The report outlines the continuous supervision and monitoring responsibilities of the sponsor, Fangzheng Securities, for Shanghai Sailun Biotechnology Co., Ltd. (Sailun Bio) following its initial public offering on the STAR Market, emphasizing compliance with relevant regulations and the company's operational status [1]. Continuous Supervision Work Situation - The sponsor has established and effectively implemented a continuous supervision work system, including a work plan tailored to specific supervisory tasks [2]. - A continuous supervision agreement was signed with Sailun Bio, clarifying the rights and obligations of both parties during the supervision period [2]. - The sponsor conducts regular communication, site visits, and due diligence to understand Sailun Bio's operational conditions [2][3]. - The sponsor ensures that Sailun Bio complies with laws, regulations, and business rules issued by the Shanghai Stock Exchange [2][3]. - The sponsor monitors the company's governance structure and internal control systems, ensuring they are effectively executed [2][3]. Financial Performance - In 2024, Sailun Bio reported a revenue of approximately 194.92 million yuan, a 2.51% increase from 2023 [9]. - The net profit attributable to shareholders was approximately 44.29 million yuan, reflecting a 14.23% increase year-on-year [9]. - The net cash flow from operating activities increased by 53.12% to approximately 50.25 million yuan [9]. - The company's total assets decreased by 0.75% to approximately 1.12 billion yuan, while net assets increased by 0.89% to approximately 1.10 billion yuan [9]. Core Competitiveness - Sailun Bio has developed a strong competitive advantage in the research and production of antivenom and antitoxin products, with proprietary technologies and patents in various critical processes [11][12]. - The company is the sole domestic producer of specific antivenom products, enhancing its market position [11]. - Continuous innovation and improvement in production processes have led to significant advancements in product quality [11][12]. Research and Development Progress - The R&D expenditure accounted for 12.23% of revenue, a decrease of 3.76 percentage points compared to the previous year [16]. - Key R&D projects are progressing steadily, including the development of antivenom for pit viper bites and honeybee venom, with clinical trials and regulatory submissions underway [17]. - The company is also focusing on improving the production processes of existing products, which has yielded significant results [17]. Use of Raised Funds - The company raised approximately 89.38 million yuan from its IPO, with net proceeds of about 78.49 million yuan after deducting issuance costs [18]. - As of December 31, 2024, the company had utilized approximately 235.99 million yuan of the raised funds, maintaining compliance with regulatory requirements regarding fund usage [18].

关于上海赛伦生物技术股份有限公司 方正证券承销保荐有限责任公司 2024 年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司自律监管指引第 11 号—持续督导》《科创板 上市公司持续监管办法（试行）》等有关法律、法规的规定，方正证券承销保荐 有限责任公司（以下简称"保荐机构"）作为上海赛伦生物技术股份有限公司（以 下简称"赛伦生物"、"公司"）首次公开发行股票并在科创板上市的保荐机构， 履行持续督导职责，并出具 2024 年度持续督导跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | 保荐机构已建立健全并有效执行 | | | --- | --- | --- | --- | --- | | 建立健全并有效执行持续督导工作制度，并针对 | 了持续督导制度，并制定了相应的 | 1 | 具体的持续督导工作制定相应的工作计划 | | | 工作计划 | 根据中国证监会相关规定，在持续督导工作开始 | | | | | 保荐机构已与赛伦生物签订《持续 | 前，与上市公司或相关当事人签署持续督导协 | 督导协议》，该协议明确了双方在 | 2 | | | ...

证券代码：688163 证券简称：赛伦生物 公告编号：2025-013 上海赛伦生物技术股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 16 日 （二） 股东大会召开的地点：上海赛伦生物技术股份有限公司（上海市青浦区 华青路 1288 号）会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 55 | | --- | --- | | 普通股股东人数 | 55 | | 2、出席会议的股东所持有的表决权数量 | 68,089,917 | | 普通股股东所持有表决权数量 | 68,089,917 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 62.9180 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 62.9 ...